» Articles » PMID: 28341852

Profiling of Long Non-coding RNAs Identifies LINC00958 and LINC01296 As Candidate Oncogenes in Bladder Cancer

Abstract

Aberrant expression of long non-coding RNAs (lncRNAs) has been regarded as a critical component in bladder cancer (BC) and lncRNAs have been associated with BC development and progression although their overall expression and functional significance is still unclear. The aim of our study was to identify novel lncRNAs with a functional role in BC carcinogenesis. RNA-sequencing was used to identify aberrantly expressed lncRNAs in 8 normal and 72 BC samples. We identified 89 lncRNAs that were significantly dys-regulated in BC. Five lncRNAs; LINC00958, LINC01296, LINC00355, LNC-CMC1-1 and LNC-ALX1-2 were selected for further analyses. Silencing of LINC00958 or LINC01296 in vitro reduced both cell viability and migration. Knock-down of LINC00958 also affected invasion and resistance to anoikis. These cellular effects could be linked to direct/indirect regulation of protein coding mRNAs involved in cell death/survival, proliferation and cellular movement. Finally, we showed that LINC00958 binds proteins involved in regulation and initiation of translation and in post-transcriptional modification of RNA, including Metadherin, which has previously been associated with BC. Our analyses identified novel lncRNAs in BC that likely act as oncogenic drivers contributing to an aggressive cancerous phenotype likely through interaction with proteins involved in initiation of translation and/or post-transcriptional modification of RNA.

Citing Articles

Anoikis-related signature identifies tumor microenvironment landscape and predicts prognosis and drug sensitivity in colorectal cancer.

Pan Y, Xu W, Huang M, Lu Y, Zhou Y, Teng Y J Cancer. 2024; 15(3):841-857.

PMID: 38213716 PMC: 10777033. DOI: 10.7150/jca.91627.


Current insights into the oncogenic roles of lncRNA LINC00355.

Shen J, Su X, Pan M, Wang Z, Ke Y, Wang Q Cancer Innov. 2023; 2(6):448-462.

PMID: 38125763 PMC: 10730005. DOI: 10.1002/cai2.91.


Development of a prognostic model for anoikis and identifies hub genes in hepatocellular carcinoma.

Zhong Z, Xie F, Yin J, Zhao H, Zhou Y, Guo K Sci Rep. 2023; 13(1):14723.

PMID: 37679418 PMC: 10484901. DOI: 10.1038/s41598-023-41139-9.


Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis.

Salamini-Montemurri M, Lamas-Maceiras M, Lorenzo-Catoira L, Vizoso-Vazquez A, Barreiro-Alonso A, Rodriguez-Belmonte E Int J Mol Sci. 2023; 24(13).

PMID: 37445988 PMC: 10341812. DOI: 10.3390/ijms241310798.


Comprehensive analysis of anoikis-related lncRNAs for predicting prognosis and response of immunotherapy in hepatocellular carcinoma.

Du S, Cao K, Wang Z, Lin D IET Syst Biol. 2023; 17(4):198-211.

PMID: 37417684 PMC: 10439496. DOI: 10.1049/syb2.12070.


References
1.
Ulitsky I, Bartel D . lincRNAs: genomics, evolution, and mechanisms. Cell. 2013; 154(1):26-46. PMC: 3924787. DOI: 10.1016/j.cell.2013.06.020. View

2.
Sarkar D, Fisher P . AEG-1/MTDH/LYRIC: clinical significance. Adv Cancer Res. 2013; 120:39-74. PMC: 3924591. DOI: 10.1016/B978-0-12-401676-7.00002-4. View

3.
Sanchez Y, Segura V, Marin-Bejar O, Athie A, Marchese F, Gonzalez J . Genome-wide analysis of the human p53 transcriptional network unveils a lncRNA tumour suppressor signature. Nat Commun. 2014; 5:5812. PMC: 4284803. DOI: 10.1038/ncomms6812. View

4.
Britze A, Birkler R, Gregersen N, Ovesen T, Palmfeldt J . Large-scale proteomics differentiates cholesteatoma from surrounding tissues and identifies novel proteins related to the pathogenesis. PLoS One. 2014; 9(8):e104103. PMC: 4122447. DOI: 10.1371/journal.pone.0104103. View

5.
Nordentoft I, Birkenkamp-Demtroder K, Agerbaek M, Theodorescu D, Stampe Ostenfeld M, Hartmann A . miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genomics. 2012; 5:40. PMC: 3473298. DOI: 10.1186/1755-8794-5-40. View